Oruka Therapeutics
ORKA

Oruka Therapeutics (ORKA) earnings history

Most recent quarter

Period end
Jun 30, 2025
EPS actual
−$0.46
EPS estimate
−$0.49
Revenue
$0.00
Reported
Aug 11, 2025

The latest quarter in Oruka Therapeutics' table is Q2 2025, reported on August 11, 2025. Oruka posted a loss of $0.46 per share, narrower than the expected loss of $0.49, a beat of 6.14%. No revenue figures or revenue estimates are given. A year earlier, in Q2 2024, the loss was $0.76 per share, so the loss narrowed by about 39%.

The record is short and has a long gap. The table holds five quarters from Q1 2020 to Q2 2021, then nothing until Q2 2024. Every quarter shown was a loss. The 2020 and 2021 losses ran from $3.96 to $9.96 per share, far larger than the losses from 2024 on, which ranged from $0.40 to $1.46 per share. No fiscal year has all four quarters in the table. Oruka beat the EPS estimate in 8 of the 10 quarters shown, missed once, in Q3 2024 by 263.27%, and showed no surprise for Q2 2024, when the estimate was listed as $0.00.

The table has no results after Q2 2025. Q3 results came out on November 2, 2020 and November 13, 2024, but the timing of the next report cannot be read from this record.

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2025Aug 11, 2025−$0.49−$0.46+6.14%$0.00SEC
Q1 2025May 14, 2025−$0.51−$0.40+21.31%$0.00SEC
Q4 2024Mar 6, 2025−$0.68−$0.49+28.13%$0.00SEC
Q3 2024Nov 13, 2024−$0.40−$1.46−263.27%$0.00SEC
Q2 2024Aug 1, 2024$0.00−$0.76+0.00%$0.00SEC
Q2 2021Aug 4, 2021−$28.44−$4.08+85.65%$0.00SEC
Q1 2021May 11, 2021−$22.44−$3.96+82.35%$0.00SEC
Q3 2020Nov 2, 2020−$30.12−$3.96+86.85%$0.00SEC
Q2 2020Aug 5, 2020−$30.96−$8.76+71.71%$0.00SEC
Q1 2020May 6, 2020−$24.48−$9.96+59.31%$0.00—

Quarterly revenue

Q1 2020
$0.00
Q2 2020
$0.00
Q3 2020
$0.00
Q1 2021
$0.00
Q2 2021
$0.00
Q2 2024
$0.00
Q3 2024
$0.00
Q4 2024
$0.00
Q1 2025
$0.00
Q2 2025
$0.00

Frequently asked questions

  • When did Oruka Therapeutics (ORKA) last report earnings?

    Oruka Therapeutics last reported on Aug 11, 2025, covering fiscal Q2 2025.

  • Did ORKA beat earnings estimates?

    Yes. Oruka Therapeutics reported EPS of −$0.46 for Q2 2025 against a −$0.49 estimate — a 6.14% beat.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.